Funded Startups in A Coruña
Among the 7 most recent funded startups listed for A Coruña, the only disclosed round above $5M is Insurama’s $6M (2024-09-05).
Among the 7 most recent funded startups listed for A Coruña, the only disclosed round above $5M is Insurama’s $6M (2024-09-05). That figure sits above Barkibu’s $5M (2023-05-04) and well beyond the rest of the disclosed amounts, which range down to $1M for Docuten (2022-07-01) and $500K for Arengu (2020-02-11). A clear temporal cluster also appears: three disclosed deals fall between May–September 2024 (Appentra on 2024-05-07 is undisclosed; Insurama at $6M on 2024-09-05; HEALTH IN CODE on 2026-02-12 is outside that window), while the remaining disclosed rounds are spaced from 2023–2020. Sector concentration shows in repeat categories: Biotechnology appears in 2 rows (HEALTH IN CODE on 2026-02-12 and Qubiotech on 2023-05-08), and Artificial Intelligence appears in 2 rows (Appentra on 2024-05-07 and Barkibu on 2023-05-04). The stage labels are broad or missing: 5 of 7 rows are “Series Unknown” and 1 of 7 is “undisclosed” (HEALTH IN CODE on 2026-02-12), with dates spanning 2020-02-11 (Arengu) through 2026-02-12 (HEALTH IN CODE).
Most recent rounds
7 shownRelated listings
Frequently asked
What’s the largest disclosed round in this A Coruña list, and how sharply does it stand out from the rest?
Insurama’s $6M on 2024-09-05 is the largest disclosed amount shown. It is above Barkibu’s $5M (2023-05-04), and the next disclosed figures are much smaller at $1M for Docuten (2022-07-01) and $500K for Arengu (2020-02-11).
Are the funded rounds clustered in a specific time window, or spread out evenly?
The disclosed amounts are concentrated around the 2022–2024 period, with Docuten at $1M on 2022-07-01 and the two largest disclosed rounds occurring in 2023–2024 (Barkibu $5M on 2023-05-04; Insurama $6M on 2024-09-05). Beyond that, Arengu’s $500K (2020-02-11) is an earlier edge, while HEALTH IN CODE (2026-02-12) is the latest edge but is undisclosed.
Which sectors appear repeatedly, and do they account for most of the entries?
Artificial Intelligence shows up twice (Appentra on 2024-05-07 and Barkibu on 2023-05-04), and Biotechnology also appears twice (HEALTH IN CODE on 2026-02-12 and Qubiotech on 2023-05-08). With only 7 rows total, these repeated sectors remain a minority of the list rather than a majority.
How does the “Series Unknown” and “undisclosed” pattern affect what analysts can compare here?
5 of 7 entries are labeled “Series Unknown” in the Series column, and 1 of 7 is explicitly “undisclosed” for the amount (HEALTH IN CODE on 2026-02-12). Only 4 entries show disclosed amounts ($6M, $5M, $1M, $500K), which limits cross-round comparisons by stage and size.
Are there outliers worth prioritizing for outreach or diligence?
Insurama’s $6M (2024-09-05) is the clear size outlier among disclosed amounts, with the rest clustering at or below $5M and falling to $1M and $500K. At the other extreme, HEALTH IN CODE (2026-02-12) is the only latest entry with an undisclosed amount, which makes it a data-gap outlier for valuation or partner sizing.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.